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Abstract
Background: The epidermal growth factor receptor
HER2 is overexpressed or amplified in 25%–30% of
patients with breast cancer. The mechanism behind
HER2 amplification is unknown, but may be a patho-
physiological phenomenon caused by continuous
stimulation and activation of the HER1-4 system. We
have mapped the protein concentrations of HER1-4 in
breast cancer tissue, autologous reference tissue, nor-
mal breast tissue and serum samples, to see whether
non-cancer cells from these patients express a protein
profile indicating general activation.
Methods: Tissue samples from malignant and adja-
cent normal breast tissue (autologous reference tis-
sue) were collected from 118 women consecutively
admitted for surgical treatment of breast cancer. In
addition, 26 samples of normal breast tissue were col-
lected from healthy women having breast reduction
surgery. The tissue samples were homogenized and
the proteins extracted. The tissue and serum concen-
trations of HER1-4 were determined quantitatively
using a commercially available enzyme linked immu-
nosorbent assay (ELISA) method.
Results: HER1 was down regulated in cancer tissue
when compared to autologous reference tissue
(ps8=10y6), while HER2 (p-10y7) and HER3 (ps3=
10y5) were up regulated. Comparing autologous ref-
erence tissue with normal tissue showed down reg-
ulation of HER1 (ps0.122) and up regulation of HER2
(ps10y6), HER3 (p-10y7) and HER4 (p-10y7).
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Furthermore, we observed that correlations between
the receptor combinations HER1-2, HER1-3 and HER1-
4 were maintained from normal breast tissue to auto-
logous reference breast tissue, but were lost in cancer
tissue.
Conclusions: We suggest that these findings indicate
that breast cancer is a systemic disease where the
HER1-4 system in autologous reference tissue is con-
tinuously activated, thus favoring the subsequent
development of cancer.
Clin Chem Lab Med 2009;47:977–84.
Keywords: breast cancer; breast tissues; epidermal
growth factor receptor (EGFR); enzyme linked immu-
nosorbent assay (ELISA); epidermal growth factor
receptor; ErbB; human epidermal growth factor recep-
tor (HER).
Introduction
The epidermal growth factor family of tyrosine
kinases includes four receptor members: HER1 wepi-
deral growth factor receptor (EGFR)/ErbB1x, HER2
(ErbB2/Neu), HER3 (ErbB3) and HER4 (ErbB4). All
receptors are structurally similar and consist of an
extracellular region binding ligands, a transmem-
brane domain and an intracellular tyrosine kinase
domain. A number of ligands have been identified
which induce homo- or heterodimerization of the
receptors following binding. This results in phospho-
rylation and activates the next step in the pathway
leading to cell growth and proliferation (1).
HER2 has been thoroughly investigated and it is
well established that this receptor is expressed at
higher than normal concentrations in 25%–30% of
patients with breast cancer (2–4). It has been docu-
mented that HER2 overexpression is associated with
shorter disease free survival and overall survival
(3–5). Treatment using the anti-HER2-specific human-
ized monoclonal antibody trastuzumab (Herceptin)
has been shown to increase survival time in these
patients (6, 7). The possible role of HER1, HER3 and
HER4 in breast cancer needs further elucidation. They
are interesting because of their ability to heterodi-
merize with HER2 and theoretically, HER2 being with-
out any known ligand, overexpression of HER2 could
be caused by HER1 stimulation.
The aim of this study was to investigate the protein
concentrations of HER1-4 in breast cancer tissue and
blood, autologous reference tissue and normal breast
tissue. We have previously shown that the concentra-
tion of HER2 in autologous reference tissue is higher
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Table 1 Pathological data in 118 breast cancer patients.






















than normal (8). This has prompted us to investigate
if this phenomenon also was true for the other recep-
tors, indicating systemic activation of the cells. The
HER1-4 findings were compared with estrogen recep-
tor (ER) status, tumor grade, axillary node status,




We obtained approval by the Regional Science Ethics Com-
mittee of Fyns and Vejle Counties (no S-VF-20040101). Fresh
breast tissue samples of malignant and adjacent normal
autologous reference tissue were collected from 118 women
admitted consecutively for surgical treatment of primary
breast cancer between 2004 and 2005. The patients under-
went surgery according to standard Danish Breast Cancer
Guidelines (DBCG) (www.DBCG.dk). The autologous refer-
ence tissue was collected at least 1 cm away from the tumor
and determined macroscopically to be tumor free by a
pathologist (Birthe Østergaard), while micro ductal carcino-
ma in situ (DCIS) cells were not searched for. The patholog-
ical characteristics of the patients are summarized in Table
1. The tissue samples were immediately frozen and stored
at y808C. In addition, normal breast tissue was collected
from 26 healthy women who underwent cosmetic breast
surgery. Tissue samples were homogenized as described in
Olsen et al. (8) and the protein concentration of each sample
was determined using the bicinchoninic acid protein assay
(Pierce, Rockford, USA). Blood samples were available for
114 cancer patients. These were collected prior to surgery
and left to coagulate for 30–60 min, followed by centrifuga-
tion at 2000=g for 10 min. Serum samples were immediately
processed and stored at y808C.
HER1 ELISA
A commercially available enzyme linked immunosorbent
assay (ELISA) (Oncogene Science, Cambridge, MA, USA)
was used to quantify HER1 in breast tissue and in serum.
Serum was diluted 50= according to the manufacturer’s
instructions and tissue extracts were diluted in sample dil-
uent provided with the kit to achieve a final protein concen-
tration of 70 mg/mL. Diluted tissue samples along with
standards and controls were added to a 96 well microtiter
plate coated with mouse monoclonal anti- (HER1) antibody
and incubated for 1.5 h at 378C. After this incubation step,
plates were washed and incubated with an alkaline phos-
phatase-labeled mouse monoclonal anti- (HER1) antibody for
0.5 h at room temperature (RT). Enzymatic reactions were
performed at RT by adding BluePhos substrate and the reac-
tion was terminated after 1.0 h by the addition of stop solu-
tion. Color development was measured at 650 nm using a
plate reader Vmax (Molecular devices, Sunnyvale, CA, USA)
and the HER1 concentrations in the unknown samples were
estimated from the standard curve. All samples were ana-
lyzed in duplicate and the average recorded. The total coef-
ficient of variation was below 7%.
HER2 ELISA
A commercially available ELISA kit (Oncogene Science,
USA) was used to quantify HER2 in tissue as described pre-
viously (8). In brief, samples were diluted to a final protein
concentration of 70 mg/mL and dispensed, along with stan-
dards and controls, in duplicate into a 96 well plate coated
with a monoclonal anti-HER2 antibody. The total coefficient
of variation was -8%. Serum samples were analyzed with
the HER2/neu assay using the ADVIA Centaur system (Bayer,
Leverkusen, Germany) according to the manufacturer’s
instructions.
HER3 ELISA
A commercially available DuoSet ELISA Development kit
(R&D Systems, Minneapolis, MN, USA) was used to quantify
HER3 in breast tissue and in serum. The plate was coated
with a mouse anti-human HER3 antibody using 4.0 mg/mL
and left to stand overnight (ON) at RT. The plate was washed
in phosphate buffered saline (PBS) containing 0.05%
Tween20, blocked for 1 h using PBS with 1% bovine serum
albumin (BSA) and washed again. Tissue extracts were dilut-
ed in PBS with 1% BSA to a final protein concentration of
70 mg/mL and serum samples were diluted 10=. Diluted
samples, along with standards and controls, were dispensed
in duplicate into a 96 well plate and incubated for 2 h at RT.
The plate was washed and incubated for 2 h at RT in the
presence of a biotinylated mouse anti-human HER3 antibody
using 0.5 mg/mL. After washing horseradish peroxidase
(HRP), conjugated Streptavidin was added and the plate was
left to stand for 30 min at RT. The plate was washed and
developed using a 1:1 mixture of tetramethylbenzidine and
H2O2. The reaction was stopped after a 30-min incubation at
RT using 2 N H2SO4. Bound HER3 was detected by measur-
ing the absorbance at 450 nm using a plate reader Vmax
(Molecular devices, USA). The HER3 concentration in the
samples was determined from the standard curve. The total
coefficient of variation was -14%.
HER4 ELISA
A commercially available DuoSet ELISA Development kit
(R&D Systems, USA) was used to quantitate HER4 in breast
tissue and serum. The procedure was identical to the HER3
assay described previously, with a few adjustments. The
coating antibody was a mouse anti-human HER4 antibody at
4.0 mg/mL, and the detection antibody was a biotinylated
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Table 2 HER1-4 protein concentrations in different groups.
HER1 HER2 HER3 HER4
Normal tissue
Range, pg/mg protein (1195–11,997.7) (208.5–13,783.4) (25.3–1574.2) (4.0–165.7)
Median, pg/mg protein 6479 1293.8 232.9 50.1
Autologous reference tissue
Range, pg/mg protein (453–22,518) (660–60,000) (133–14,426) (20–4272)
Median, pg/mg protein 5166 6091 1960 516
p-Value 0.122 10y6 -10y7 -10y7
Cancer tissue
Range, pg/mg protein (267–45,803) (3498–2,034,610) (373–26,240) (26–4133)
Median, pg/mg protein 3309 31,656 3213 421
p-Value 8=10y6 -10y7 3=10y5 0.720
Serum
Range, pg/mL (39,100–88,000) (6100–23,300) (1000–45,100) (0.49–129.3)
Median, pg/mL 59,500 11,400 1900 5.6
p-Values in the autologous reference tissue group refer to differences in medians between normal tissue and autologous
reference tissue (Mann-Whitney U-test). p-Values in the cancer tissue group refer to differences in medians between auto-
logous reference tissue and cancer tissue (Wilcoxon test).
mouse anti-human HER4 antibody at 0.25 mg/mL. Breast
tissue extracts were diluted to a protein concentration of 80
mg/mL, and serum was applied undiluted. The total coeffi-
cient of variation was -13%.
ER status by immunohistochemistry (IHC)
IHC was performed on formalin-fixed paraffin-embedded
breast tissue sections. The slides were deparafinized and
rehydrated in graded alcohol solutions. Slides were incubated
with a 1:150 dilution of a mouse anti-human estrogen recep-
tor mab (clone 1D5, Dakocytomation, Glostrup, Denmark) for
30 min. Visualization of the reaction was performed using
Super Sensitive Polymer-HRP IHC kit (Biogenix, San Ramon,
CA, USA). Tumors with staining of 10% or more of the nuclei
were considered to be ER positive according to standard
Danish Breast Cancer Guidelines (www.DBCG.dk).
Statistical methods
Data were evaluated using NCSS software (version 2004,
Kaysville, UT, USA) to perform the following statistical anal-
yses: Wilcoxon Signed Ranks test, Mann-Whitney U-test,
Spearman’s r, Kruskal-Wallis test, Kaplan-Meier and log-
rank test.
Results
HER1-4 measurements in breast tissues
The level of HER1 was decreased by 20% in auto-
logous reference tissue when compared to normal
tissue. HER2, HER3 and HER4 were significantly
increased (Table 2, Figure 1). In cancer tissue, HER1
was significantly reduced when compared to normal
and autologous reference tissue, while HER2 and
HER3 were significantly increased. The level of HER4
was increased to the same degree in the autologous
reference and cancer tissue (Table 2, Figure 1).
Dividing patients into negative and positive groups
according to HER2 status as determined by IHC and
fluorescence in situ hybridization (FISH) showed no
significant differences for HER1, 3 and 4 in the auto-
logous reference tissue. In addition, the differences
with respect to the normal tissue were maintained. In
HER2 negative and positive cancer tissue, the concen-
tration of HER1 and 3 showed no differences, while
HER4 was significantly lower in the HER2 positive
group (ps0.004). In the HER2 negative paired groups
of autologous reference tissue and cancer tissue, sig-
nificant differences were found for HER1 (ps4=10y5)
and HER3 (ps7=10y5) but not for HER4. In the HER2
positive paired groups of autologous reference tissue
and cancer tissue, no differences were observed.
HER1-4 correlations
The HER1-4 receptors in normal tissues were corre-
lated significantly between HER1-2, HER1-3, HER1-4
and HER2-3 (Table 3). Furthermore, associations
between receptors in autologous reference tissue
were studied and significant correlation was found
between all receptors (Table 3). In cancer tissue, sig-
nificant correlations were found between HER2-3 and
HER3-4 (Table 3).
HER1-4 measurements in serum
HER1-4 concentrations were quantitated in 114 serum
samples (Table 2). The values were compared with
corresponding HER1-4 measurements in cancer and
autologous reference tissue, but no correlation was
found. Correlation between the receptors in serum
were studied; significant correlations were found
between HER1-3, HER2-4 and HER3-4 (Table 3).
ER status
Of the 118 patient with breast cancer, 97 (82%) were
classified as ER positive and 21 (18%) as ER negative.
The HER1 concentration was significantly higher in ER
negative tissue compared to ER positive tissue (Figure
2, Table 4). No difference was observed between ER
negative and positive tissues with respect to HER2
concentrations, while the median values of HER3 and
HER4 were significantly higher in ER positive tissues
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Figure 1 HER1-4 protein concentrations in cancer tissue, autologous reference tissue and in normal tissue quantified using
ELISA.
Table 3 Correlations between the HER1-4 receptors.
Normal tissue Autologous reference
tissue
Cancer tissue Serum
Correlation p-Value Correlation p-Value Correlation p-Value Correlation p-Value
HER1-2 0.558 0.0056 0.417 5=10y6 0.169 0.075 0.126 0.180
HER1-3 0.537 0.0047 0.427 5=10y6 0.011 0.911 0.232 0.013
HER1-4 0.570 0.0029 0.267 0.007 0.02 0.837 0.055 0.572
HER2-3 0.705 0.00017 0.294 0.002 0.379 3=10y5 0.058 0.541
HER2-4 0.254 0.243 0.217 0.029 0.079 0.417 0.192 0.044
HER3-4 0.164 0.434 0.824 -10y6 0.581 -10y6 0.212 0.025
The correlations were determined using Spearman’s r.
as compared to ER negative tissues (Figure 2, Table
4).
Clinical data
HER1-4 protein concentrations in breast cancer tissue
were compared with tumor grade, axillary node stat-
us (Table 4) and tumor size (data not shown). No sig-
nificant correlations were found. The median follow
up was 943 days (range 119–1323 days). During this
period relapses were observed in 15 patients. Patients
with high HER2 concentrations in cancer tissue using
a cut-off value of either 50,000 (Figure 3A), 100,000 or
200,000 pg/mg (data not shown) or HER3 concentra-
tions below the median had increased risk of recur-
rence (Figure 3B). Neither HER1 nor HER4 individual
expression showed significant association with dis-
ease free survival.
The impact of expression of HER1 and HER2 in
combination with HER3 and HER4 was evaluated by
categorizing patients into two groups; one with high
concentration wat or above the median (q)x and anoth-
er with low concentration wbelow the median (–)x. The
patients were divided into the following groups:
Group (a) patients with high HER2, HER3 and HER4,
(b) low HER2 and high HER3 and HER4, (c) low HER2,
HER3 and HER4 (d) high HER2 and low HER3 and
HER4, (e) high HER2, high HER3 and low HER4 or high
HER2, low HER3 and high HER4, (f) low HER2, high
HER3 and low HER4 or low HER2, low HER3 and high
HER4. The same grouping was performed for HER1,
HER3 and HER4 receptor combinations (Figure 3C and
D). Disease free survival between all groups was not
significant. However, patients with high HER2 com-
bined with high HER3 and HER4 had longer disease
free survival compared to patients with high HER2
combined with low HER3 and HER4 (ps0.038) (Figure
3C, a compared with d).
Discussion
To our knowledge, we are the first to apply a quanti-
tative method to determine HER1-4 protein concentra-
tions in autologous reference tissue and compare
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Figure 2 HER1-4 protein concentrations in breast cancer tissue divided according to ER positivity.
Table 4 Relationships between HER1-4 in cancer tissue and pathological parameters.
n HER1, pg/mg HER2, pg/mg HER3, pg/mg HER4, pg/mg
Median (range) Median (range) Median (range) Median (range)
Axillary node status
– 49 3244 (267–9308) 33,141 (3498–2,034,610) 3101 (811–26,242) 497 (79–4133)
q 69 3240 (341–45,803) 31,656 (5814–964,220) 3255 (373–12,000) 406 (26–2225)
p-Value 0.978 0.593 0.783 0.322
Tumor grade
1 20 3863 (719–8729) 31,656 (6241–295,610) 3213 (948–9799) 531 (280–2166)
2 51 3560 (267–45,803) 25,619 (3498–402,690) 3749 (516–13,112) 555 (26–4133)
3 41 2991 (392–17,774) 34,354 (4833–2,034,610) 2947 (373–26,242) 351 (59–1519)
p-Value 0.552 0.892 0.575 0.130
ER
– 21 5166 (719–17,774) 31,482 (5814–2,034,610) 2215 (373–5561) 250 (59–815)
q 97 3039 (267–45,803) 33,141 (3498–1,358,800) 3758 (516–26,242) 521 (26–4133)
p-Value 0.0025 0.582 0.0013 0.00059
Statistical analysis applied was Wilcoxon test (axillary node status and ER status) and Kruskal-Wallis test (tumor grade). ER,
estrogen receptor.
these concentrations to concentrations in cancer tis-
sue and normal breast tissue. We have previously
shown that HER2 is up regulated in autologous ref-
erence tissue compared to normal breast tissue (8).
Therefore, we hypothesized that HER1, 3 and 4 in
autologous reference tissue might follow a similar
pattern, and change in a way that is characteristic for
cancer tissue and that differs from normal breast
tissue.
The results showed down regulation of HER1 and
up regulation of HER2-4 in autologous reference tis-
sue and cancer tissue compared to normal breast tis-
sue. Other authors have also examined HER1-4 using
other methods including IHC, FISH, real-time reverse
transcription-polymerase chain reaction (RT-PCR) and
Western blotting (9–12). Previous reports have shown
an increased content of HER2 and HER3 in breast
cancer tissue as compared to normal tissues (13–15)
which are in agreement with our results. Furthermore,
the observation that HER1 is decreased in cancer tis-
sue as compared to normal tissue has been described
previously in the literature for breast cancer (15, 16)
as well as other malignancies such as ovarian cancer
(17). The reason for the decreased concentration of
HER1 in cancer tissue is unknown, however, it has
been suggested that it could be due to a system in
which HER1 is constantly activated followed by inter-
nalization, ubiquination and degradation resulting in
a decreased HER1 concentration (17). This suggestion
is based on the observation that HER1 gene expres-
sion is similar in normal and cancerous tissue. In
addition, it has been shown that most HER1 is inter-
nalized following ligand binding and ultimately
degraded in lysosomes; HER2-4 receptors are endo-
cytosis impaired, and are more often recycled back to
the cell surface (18, 19).
Significant correlations were found between all the
receptor combinations in the autologous reference
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Figure 3 Kaplan-Meier curves showing disease free survival of HER2 and HER3 expressed individually (A and B) and of
various HER1-4 receptor combinations (C and D).
p-Value represents log-rank difference in disease free survival between two groups (A and B) and all groups (C and D).
tissue. However, in cancer tissue the correlations
between HER1-2, HER1-3, HER1-4 and HER2-4 were
lost. Since these patients had not yet received treat-
ment, and the changes in quantitative measurements
of the receptors are reliable, we believe that this
reflects the changes occurring during the develop-
ment of cancer. These results are in agreement with
a report by Bianchi et al. (20), but not with the findings
of Abd El-Rahim et al. (21). Reasons for these discrep-
ancies could be due to the detection methods used,
the antibodies used or patient material. The signifi-
cant correlation found between HER2-3 and HER3-4 in
breast cancer tissue is in agreement with previous
studies that have suggested a significant role of HER2
and HER3 heterodimers in breast tumorigenesis (9,
10, 13, 20).
We demonstrate that patients with high concentra-
tions of HER2 or low concentrations of HER3 in breast
cancer tissue had increased risk for relapse, while
HER1 and HER4 by themselves showed no prognostic
value. In addition, combining high expression of
HER2 in combination with high concentrations of
HER3 and HER4 showed increased disease free sur-
vival time compared to high concentrations of HER2
in combination with low concentrations of HER3 and
HER4. This shows that expression of HER3 and HER4
can influence the effect of HER2 on disease free
survival.
The majority of authors describe increased expres-
sion of HER1 or HER2 to be associated with unfavor-
able prognosis (3, 4, 12, 21). However, some authors
found no prognostic value of HER1 (22, 23) or HER2
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(10, 24). The follow up time, number of patients and
the detection method may explain these differences.
Most studies show high concentrations of HER3 or
HER4 to be associated with improved disease free
and overall survival (10–13, 23), which are in agree-
ment with our results. The counteracting effect of
high HER3 and HER4 on disease free survival that we
observed is comparable to a previous study per-
formed on patients with bladder cancer (25).
The primary focus of our study was to investigate
whether the pronounced changes seen in the receptor
concentrations HER1-4 in breast cancer tissue, com-
pared to normal breast tissue from healthy women,
could be found also in the autologous reference tis-
sue. This was found to be correct and might be due
to carcinoma cells in the reference tissue. As the tis-
sue pathology was examined, it was shown to be free
of invasive growth, but as micro DCIS cells were not
specifically looked for, DCIS could be the cause. Other
authors have shown that a free margin to the primary
tumor of 1 cm reduces the risk of local recurrence in
adjacent tissue to a minimum (26, 27). However, pre-
vious work showed a risk of multifocality (28). We per-
formed an extensive literature search and were
unable to find systematic sectional investigations of
breast tissue after mastectomy to document this.
Whatever the explanation, DCIS or general activation
of normal cells, our findings show that the disease is
not limited to the tumor itself, but also to the sur-
rounding cells. Therefore, we suggest that the char-
acteristic changes in cancer tissue are mirrored in the
autologous reference tissue.
In conclusion, these results point to a continuum in
the process of cancer development. Step 1 being a
change in stimulation of growth factor receptors as
indicated by changes in the concentration of recep-
tors, even in autologous reference tissue. In step 2,
deregulated expression occurs where the normal cor-
relations between receptor concentrations are lost. To
further investigate this, a new study is planned for a
cohort of patients with measurement of HER1-4 con-
centrations in tissue, relevant ligands and receptor
activation as evidenced by phosphorylation.
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